Clinical trials: End-stage Heart Failure
Heart Failure, Ventricular Assist Device
Influence of Telemonitoring on the Management of LVAD-patients
The current study aims to investigate whether telemedical monitoring in patients with terminal heart failure and an implanted left ventricular assist device (LVAD) has an influence on LVAD-associated complications…
- Conditions
- Heart Failure, Ventricular Assist Device, Telemedicine
- Trial name
- NCT04613401
- Testing
- questionnaire (observational study)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital, Essen
Infective Endocarditis, End Stage Renal Disease
Incidence of Infective Endocarditis in End Stage Renal Disease Patients on Hemodialysis by Transesophageal Echocardiography in Assuit University Hospital
1. To detect in more detail the incidence of infective endocarditis in patients with end stage renal disease (ESRD) on hemodialysis. 2.
- Trial name
- NCT05692089
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
End-Stage Renal Disease, Hemodialysis
Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis
The investigators hypothesize that an increase in the duration of dialysis session in thrice weekly center hemodialysis may provide better outcome, less morbidity, higher quality of life, lesser requirement of medications, and…
- Trial name
- NCT00413803
- Testing
- 4-hour thrice weekly in center hemodialysis, 8-hour thrice weekly in center hemodialysis
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 410 people
- Sponsor
- Ege University
Complication of Hemodialysis, Cardiovascular Diseases
Sodium Thiosulfate Treatment of Vascular Calcification in ESRD
Cardiovascular disease is the major cause of death in the hemodialysis population and calcification of the major arteries (coronary, aorta, and carotid) are a play a central role in this process.
- Trial name
- NCT00568399
- Testing
- sodium thiosulfate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Sudden Cardiac Death, End Stage Renal Disease
T-Wave Alternans in Dialysis Patients
Sudden cardiac death due to arrhythmia is the leading cause of death in end-stage renal disease (ESRD) patients treated with hemodialysis (HD).
- Trial name
- NCT00621426
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Heart Failure, Congenital
Etablishment of Follow-up System and End-Stage Heart Registration Platform for Pediatric Heart Failure
Establish a follow-up management system for pediatric heart failure and a registration platform for end-stage heart failure
- Conditions
- Heart Failure, Congenital, End-stage Heart Failure
- Trial name
- NCT06345521
- Testing
- No intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- China National Center for Cardiovascular Diseases
End-stage Heart Failure
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
In the DAPA-HF trial, the use of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduced significantly the risk of worsening heart failure or death from cardiovascular causes compared to placebo among…
- Trial name
- ARCADIA-HF (NCT04782245)
- Testing
- Dapagliflozin 10mg
- Where
- France
- Sponsor
- Hospices Civils de Lyon
End Stage Renal Disease, Chronic Kidney Disease
Risk Stratification in End Stage Renal Disease (ESRD) - ISAR Study
The purpose of this study is to evaluate the use of non-invasive markers of the autonomic function and micro- and macrocirculation to predict mortality and cardiovascular end points in end-stage renal disease patients.
- Conditions
- End Stage Renal Disease, Chronic Kidney Disease, Cardiovascular Event, Sudden Cardiac Death
- Trial name
- ISAR (NCT01152892)
- Where
- 17 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Technical University of Munich
Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome
Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients
Patients with kidney failure who require hemodialysis often suffer from anemia (low red blood cell count), heart and blood vessel problems, and a condition involving poor nutrition, inflammation, and hardening of the arteries…
- Conditions
- Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome, Anemia in End Stage Renal Disease, Cardiovascular Diseases (CVD)
- Trial name
- ROXA-HD-MIA (NCT06903559)
- Testing
- Roxadustat, Conventional Anemia Management
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Mansoura University
Heart Failure
Evaluation of Myocardial Improvement in Patients Supported by Ventricular Assist Device Under Optimal Pharmacological Therapy
Cardiac function may improve in patients with end-stage heart failure who receive long-term support with ventricular assist devices (VAD).
- Trial name
- NCT00402376
- Testing
- Pravastatin, Carvedilol, Perindopril, Biventricular assist device (Thoratec paracorporeal assist device)
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
End-Stage Renal Disease
Vitamin D3 Supplementation in Dialysis Patients
Vitamin D deficiency is highly prevalent among dialysis patients, and has been associated with cardiovascular risk factors such as increased aortic pulse wave velocity, blood pressure, inflammation, and brain natriuretic peptide.
- Trial name
- NCT01312714
- Testing
- Cholecalciferol
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- Regional Hospital Holstebro
End-stage Heart Failure
Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure
The study is a prospective, randomized, non-blinded, national, multi-center study. The study will consist of the assignment of eligible patients to treatment with either a HeartMate III (HM III) left ventricular assist device…
- Trial name
- SweVAD (NCT02592499)
- Testing
- HM III, OMM, optimal medical management
- Where
- 7 sites in Sweden
- Volunteers
- 74 people
- Sponsor
- Vastra Gotaland Region
End Stage Renal Disease, Coronary Heart Disease
T Wave Alternans in Hemodialysis
The purpose of this study is to determine if the hemodialysis procedure changes the risk for cardiac arrest in patients.
- Conditions
- End Stage Renal Disease, Coronary Heart Disease, Congestive Heart Failure
- Trial name
- NCT00296543
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Cardiogenic Shock, End-stage Heart Failure
ECLS Versus IMPELLA™ as Bridge to LVAD (ECI-BLAD)
In this retrospective observational multicenter study the authors tested the hypothesis that the use of IMPELLA™ pump as bridge to bridge, by giving the opportunity of active rehabilitation, should improve patient's outcomes…
- Trial name
- ECI-BLAD (NCT04480151)
- Testing
- standard of care
- Where
- 5 sites in France
- Volunteers
- 92 people
- Sponsor
- University Hospital, Bordeaux
Acute Coronary Syndrome, Chronic Kidney Disease
Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients
A 4 week-duration cross-over study on Ticagrelor and Clopidogrel for the Acute Coronary Syndrome (ACS) and Chronic Kidney Disease (CKD) subjects, focusing on the platelet inhibition and safety observation.
- Conditions
- Acute Coronary Syndrome, Chronic Kidney Disease, End-Stage Renal Disease
- Trial name
- APROVE-CKD (NCT02459288)
- Testing
- Clopidogrel first, Ticagrelor first
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Ping-Yen Liu
Cardiovascular Diseases, Carotid Intimal Media Thickness
Association of Mean Platelet Volume and Cardiovascular Disease in Children With End Stage Renal Disease.
Cardiovascular disease (CVD) is the major risk factor for death in end stage renal diseases (ESRD). Approximately 80% of ESRD patients have some degrees of left ventricular abnormalities at initiation of dialysis.
- Conditions
- Cardiovascular Diseases, Carotid Intimal Media Thickness, Left Ventricular Hypertrophy, Mean Platelet Volume
- Trial name
- NCT03759002
- Testing
- Imaging, Blood sampling
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Heart Transplantation, End-stage Heart Failure
Donor Circadian Rhythm and Its Correlation With Prognosis After Heart Transplantation
The goal of this observational study is to learn about the impact of donor heart procurement time based on circadian rhythm on the long-term outcomes of heart transplant recipients.
- Conditions
- Heart Transplantation, End-stage Heart Failure, Circadian Rhythm
- Trial name
- CIRCA-HTx (NCT07301788)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
End Stage Kidney Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Trial name
- POSIBIL6ESKD (NCT05485961)
- Testing
- CSL300
- Where
- 566 sites in United States, Argentina and 33 more
- Volunteers
- 3,110 people
- Sponsor
- CSL Behring
Heart Failure, COPD
Ultrasound in Acute Dyspnea in the Field
Acute heart failure is one of the main causes of acute respiratory distres in prehospital emergency setting. The early and correct diagnosis is important because the misdiagnosis can result in deleterious consequeance to…
- Conditions
- Heart Failure, COPD, Asthma
- Trial name
- NCT01235182
- Where
- Slovenia
- Volunteers
- 248 people
- Sponsor
- University Medical Centre Maribor
End-stage Kidney Disease
Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients
The purpose of this study is to see if vitamin K supplementation three times per week reduces the progression of coronary artery calcification over 12 months in dialysis patients compared to placebo.
- Trial name
- iPACK-HD (NCT01528800)
- Testing
- Vitamin K1, Microcrystalline Methylcellulose
- Where
- 3 sites in Canada
- Volunteers
- 85 people
- Sponsor
- Dr. Rachel Holden